Dorzolamide 2 % eye drops solution — Competitive Intelligence Brief

Dorzolamide 2 % eye drops solution (Dorzolamide 2 % eye drops solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Carbonic anhydrase inhibitor. Area: Ophthalmology.

phase 3 Carbonic anhydrase inhibitor Carbonic anhydrase II Ophthalmology Small molecule

Target snapshot

Dorzolamide 2 % eye drops solution (Dorzolamide 2 % eye drops solution) — Alfred E. Tiefenbacher (GmbH & Co. KG). Dorzolamide inhibits carbonic anhydrase II in the eye to reduce aqueous humor production and lower intraocular pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dorzolamide 2 % eye drops solution TARGET	Dorzolamide 2 % eye drops solution	Alfred E. Tiefenbacher (GmbH & Co. KG)	phase 3	Carbonic anhydrase inhibitor	Carbonic anhydrase II
Azopt	BRINZOLAMIDE	Novartis	marketed	Carbonic Anhydrase Inhibitor [EPC]	carbonic anhydrase II	1998-01-01
dorzolamide/timolol maleate fixed combination	dorzolamide/timolol maleate fixed combination	Pharmaceutical Research Network	marketed	Carbonic anhydrase inhibitor / Beta-adrenergic antagonist combination	Carbonic anhydrase II; Beta-adrenergic receptors (β1 and β2)
Drug: dorzolamide/timolol	Drug: dorzolamide/timolol	Aristotle University Of Thessaloniki	marketed	Carbonic anhydrase inhibitor / Beta-blocker combination	Carbonic anhydrase II / Beta-adrenergic receptors (β1 and β2)
Dorzolamide 2% drops	Dorzolamide 2% drops	University Health Network, Toronto	marketed	Carbonic anhydrase inhibitor	Carbonic anhydrase II
tafluprost and dorzolamide/timolol	tafluprost and dorzolamide/timolol	Aristotle University Of Thessaloniki	marketed	Prostaglandin analogue / carbonic anhydrase inhibitor / beta-blocker combination	Prostaglandin F receptor (FP receptor), carbonic anhydrase II, beta-1 and beta-2 adrenergic receptors
Cosopt PF 2%-0.5% Ophthalmic Solution	Cosopt PF 2%-0.5% Ophthalmic Solution	Prairie Eye Center	marketed	Fixed-dose combination of carbonic anhydrase inhibitor and beta-blocker	Carbonic anhydrase II (dorzolamide component); beta-adrenergic receptors (timolol component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Carbonic anhydrase inhibitor class)

1. Bausch & Lomb Incorporated · 2 drugs in this class
2. Actavis Inc. · 2 drugs in this class
3. Beijing Tiantan Hospital · 1 drug in this class
4. Merck Sharp & Dohme LLC · 1 drug in this class
5. National University Hospital, Singapore · 1 drug in this class
6. Padagis LLC · 1 drug in this class
7. Rabin Medical Center · 1 drug in this class
8. Shahid Beheshti University of Medical Sciences · 1 drug in this class
9. Sun Pharmaceutical Industries Limited · 1 drug in this class
10. University Health Network, Toronto · 1 drug in this class